SHP2 Targets ITK Downstream of PD-1 to Inhibit T Cell Function.
Sign Up to like & getrecommendations! Published in 2021 at "Inflammation"
DOI: 10.1007/s10753-021-01437-8
Abstract: PD-1 is a critical therapeutic target in cancer immunotherapy and antibodies blocking PD-1 are approved for multiple types of malignancies. The phosphatase SHP2 is the main effector mediating PD-1 downstream signaling and accordingly attempts have… read more here.
Keywords: downstream inhibit; itk downstream; shp2 targets; inhibit cell ... See more keywords